Business Context and Reporting Period
This Form 8-K Current Report from Madrigal Pharmaceuticals, Inc. (MDGL) covers events occurring on June 15, 2023, and June 16, 2023. The filing primarily reports the results of the Company's 2023 Annual Meeting of Stockholders and the subsequent filing of a Certificate of Amendment to its Restated Certificate of Incorporation.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
- Amendment to Charter: On June 16, 2023, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Delaware Secretary of State. This amendment provides exculpation from liability for certain officers regarding claims of breach of the fiduciary duty of care.
- Annual Meeting Attendance: The 2023 Annual Meeting was held virtually on June 15, 2023. As of the record date (April 27, 2023), 18,289,173 shares were outstanding. A quorum was established with 16,146,504 shares present or represented by proxy.
Voting Results and Management Commentary
Stockholders voted on four proposals at the Annual Meeting. The results were as follows:
- Proposal 1 (Election of Directors): Three Class I nominees were elected for a three-year term.
- Paul A. Friedman, M.D.: 14,114,309 votes For; 750,859 votes Withheld.
- Kenneth M. Bate: 13,914,837 votes For; 950,331 votes Withheld.
- James M. Daly: 8,913,220 votes For; 5,951,948 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP.
- Votes For: 16,111,585
- Votes Against: 12,542
- Votes Abstaining: 22,377
- Proposal 3 (Executive Compensation): Stockholders approved the advisory vote on executive compensation with 93.56% of votes cast in favor.
- Votes For: 13,908,736
- Votes Against: 940,302
- Votes Abstaining: 16,130
- Proposal 4 (Charter Amendment): Stockholders approved the amendment to the Restated Certificate of Incorporation.
- Votes For: 13,898,961
- Votes Against: 958,185
- Votes Abstaining: 8,022
Investor Verification Checklist
- Verify the specific language of the exculpation provision in the Certificate of Amendment (Exhibit 3.1) to understand the scope of liability protection for officers.
- Review the significant number of votes withheld for director nominee James M. Daly (5,951,948) compared to the other nominees to assess shareholder sentiment.
- Confirm the effective date of the charter amendment is June 16, 2023, as stated in the filing.
- Consult the Definitive Proxy Statement filed on May 1, 2023, for detailed descriptions of the proposals and executive compensation details.